The first one million doses of 13-valent pneumonia conjugate vaccine developed by China's Walvax were exported to Morocco from southwest China's Yunnan Province on May 21. The vaccine is used for the treatment of 13 common infections caused by streptococcus pneumonia bacteria in children over the age of six weeks and under six years. China independently developed a 13-valent pneumonia vaccine in 2019. Before that the only available vaccine was made by U.S. drug maker Pfizer. The vaccine has been included in Morocco's expanded program on immunization to protect children from life-threatening diseases.